Published in AIDS Res Hum Retroviruses on July 01, 1992
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol (1996) 4.81
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 2.49
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol (1993) 1.78
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. J Virol (1994) 1.36
Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR. J Virol (1995) 1.23
Quantification of human immunodeficiency virus in plasma by RNA PCR, viral culture, and p24 antigen detection. J Clin Microbiol (1994) 1.01
Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect. J Clin Microbiol (1993) 0.90
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother (1995) 0.88
Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol (1998) 0.82
The scope of quantitative polymerase chain reaction assays in clinical molecular pathology. Clin Mol Pathol (1995) 0.82
The sequence of the human genome. Science (2001) 101.55
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (1985) 5.70
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
Molecular targets for AIDS therapy. Science (1990) 4.28
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med (1989) 3.13
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol (2001) 2.82
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med (1993) 2.32
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet (2001) 2.31
Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet (1987) 2.30
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol (2000) 2.22
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
Fraud in breast-cancer trials. N Engl J Med (1994) 2.16
Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood (1999) 2.10
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc Natl Acad Sci U S A (1994) 2.09
A case of Cushing's syndrome due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy. J Urol (1997) 2.08
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem (1994) 2.03
Simultaneous induction of antigen-specific IgA helper T cells and IgG suppressor T cells in the murine Peyer's patch after protein feeding. J Immunol (1981) 2.03
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. J Clin Invest (1997) 1.98
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
Age-related changes in the subsets and functions of human T lymphocytes. J Immunol (1978) 1.82
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem (1988) 1.82
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol (1999) 1.81
Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol (1978) 1.79
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med (1978) 1.78
Age-related decline in the in vitro and in vivo syntheses of anti-tetanus toxoid antibody in humans. J Immunol (1980) 1.78
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis (1998) 1.75
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74